Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate | Johnson & Johnson

Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate

02/04/2021

DownloadPDF 205 KB

Multimedia Files:

Questions? Please contact us:

investor-relations@its.jnj.com